Tango Therapeutics (TNGX) EBITDA (2020 - 2026)

Tango Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$48.8 million for Q1 2026.

• On a quarterly basis, EBITDA fell 14.67% year-over-year to -$48.8 million in Q1 2026; TTM through Mar 2026 was -$117.5 million, a 19.43% increase from a year earlier, with the FY2025 full-year figure at -$111.3 million, up 23.56% from the prior year.
• EBITDA eased to -$48.8 million in Q1 2026 per TNGX's latest filing, from -$41.9 million in the prior quarter.
• Across five years, EBITDA topped out at $14.1 million in Q3 2025 and bottomed at -$48.8 million in Q1 2026.
• The 5-year median for EBITDA is -$30.6 million (2022), against an average of -$31.2 million.
• Across the five-year window, EBITDA slumped 453.16% in 2022 and surged 142.8% in 2025, its largest moves.
• Year by year, EBITDA stood at -$30.6 million in 2022, then slipped by 14.55% to -$35.0 million in 2023, then fell by 16.84% to -$40.9 million in 2024, then dropped by 2.33% to -$41.9 million in 2025, then declined by 16.49% to -$48.8 million in 2026.
• Per Business Quant, the three latest TNGX EBITDA figures stand at -$48.8 million (Q1 2026), -$41.9 million (Q4 2025), and $14.1 million (Q3 2025).